Consumer understanding of skin concerns with an AI-powered informational tool
Peer-Reviewed Publication
Updates every hour. Last Updated: 24-Jun-2026 08:15 ET (24-Jun-2026 12:15 GMT/UTC)
Applying new analytic methods to nearly 16,000 ancient genomes reveals natural selection has acted on hundreds, not dozens, of genes in West Eurasia over the last 10,000 years. More than half of the genes have known links to disease risk and other traits today, although it’s not yet clear what made each gene advantageous in prehistoric contexts. The work demonstrates the power of ancient DNA to illuminate human biology and medicine in addition to history.
Duracyte is a biotechnology company developing implantable “living pharmacy” devices designed to continuously produce therapeutic proteins inside the body. The company plans to initiate a Phase 1 clinical trial this year evaluating patients with recurrent ovarian cancer. Duracyte is the third company launched by RBL LLC, following Sentinel BioTherapeutics and SteerBio, reinforcing Houston’s growing role as a biotechnology innovation hub.
A joint research team led by Professor Shiqi (Shawn) Ou, Associate Professor Yahui Jia, and Associate Professor Yuan Lin from South China University of Technology, together with Associate Professor Zhixia Li from the University of Cincinnati, proposed a cross-temporal electric vehicle battery health assessment framework called D2B (Drive-to-Battery), aiming to establish a link between daily driving behavior and long-term battery health.